Exact claim · Version 1 · Reviewed
“Retatrutide is being submitted to FDA, so it will be available in 2027.”
A verdict on this wording and scope, not a universal grade for Retatrutide.
01 · Verdict
Misleading
Lilly states it plans to submit retatrutide for obesity in the first quarter of 2027. A planned submission is a future corporate action, not regulatory acceptance, approval, a prescribing label, or a launch date. Until an approval is recorded by the regulator, the accurate U.S. status remains investigational.
- Evidence basis
- Regulatory or product record
- Scope
- The sponsor-stated first-quarter 2027 U.S. submission plan as reviewed July 24, 2026.
- Category
- Approval and status
02 · Primary record
Check the attached evidence
01What to know about retatrutideEli Lilly and Company · Regulatory · 2026
Supports the corrective verdict02FDA concerns with unapproved GLP-1 drugs used for weight lossU.S. Food and Drug Administration · Regulatory · 2026
Supports the corrective verdict
Supports the corrective verdict02FDA concerns with unapproved GLP-1 drugs used for weight lossU.S. Food and Drug Administration · Regulatory · 2026
Supports the corrective verdict
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.